We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

236 hedge funds and large institutions have $3.87B invested in Ultragenyx Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 94 increasing their positions, 75 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 23

54% more capital invested

Capital invested by funds: $2.52B → $3.87B (+$1.36B)

25% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 75

8% more funds holding

Funds holding: 219 → 236 (+17)

0.1% less ownership

Funds ownership: 98.74% → 98.64% (-0.1%)

1% less call options, than puts

Call options by funds: $23.1M | Put options by funds: $23.4M

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

Holders
236
Holders Change
+17
Holders Change %
+7.76%
% of All Funds
3.44%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
44
Increased
94
Reduced
75
Closed
23
Calls
$23.1M
Puts
$23.4M
Net Calls
-$285K
Net Calls Change
-$1.62M

Top Buyers

1
Sands Capital Management
Sands Capital Management
Virginia
+$59.7M
2
RI
RTW Investments
New York
+$57.5M
3
SCM
Suvretta Capital Management
New York
+$56.1M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$55.8M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$36.2M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$44.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$30.3M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$23.8M
4
FLAM
First Light Asset Management
Minnesota
-$14.7M
5
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$9.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$415M +$55.8M +1,440,264 +20%
RI
2
RTW Investments
New York
$329M +$57.5M +1,481,997 +27%
BlackRock
3
BlackRock
New York
$251M +$6.17M +159,191 +3%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$211M -$30.3M -780,851 -15%
Sands Capital Management
5
Sands Capital Management
Virginia
$197M +$59.7M +1,540,791 +60%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$165M +$11.2M +288,538 +9%
State Street
7
State Street
Massachusetts
$156M +$26.5M +684,644 +27%
Federated Hermes
8
Federated Hermes
Pennsylvania
$117M +$9.69M +250,000 +11%
ClearBridge Investments
9
ClearBridge Investments
New York
$114M +$3.49M +89,922 +4%
Alkeon Capital Management
10
Alkeon Capital Management
New York
$107M +$11.6M +298,017 +15%
SCM
11
Suvretta Capital Management
New York
$102M +$56.1M +1,446,847 +213%
RSCM
12
Rock Springs Capital Management
Maryland
$83.9M +$10.8M +277,597 +19%
AllianceBernstein
13
AllianceBernstein
Tennessee
$75.5M +$1.79M +46,098 +3%
Marshall Wace
14
Marshall Wace
United Kingdom
$71.2M +$21.3M +548,723 +58%
BBA
15
Baker Bros. Advisors
New York
$70.1M +$3.88M +100,000 +7%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$61.4M +$7.77M +200,335 +18%
Morgan Stanley
17
Morgan Stanley
New York
$57.1M +$27.1M +699,609 +141%
Deutsche Bank
18
Deutsche Bank
Germany
$56.1M +$8.73M +225,134 +24%
First Trust Advisors
19
First Trust Advisors
Illinois
$55.6M -$1.5M -38,611 -3%
Adage Capital Partners
20
Adage Capital Partners
Massachusetts
$49M +$36.2M +935,000 +1,039%
Pictet Asset Management
21
Pictet Asset Management
Switzerland
$48.9M +$5.96M +153,748 +18%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$48.3M +$15.1M +389,124 +63%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$47.5M -$1.35M -34,834 -3%
CCM
24
Camber Capital Management
Massachusetts
$43M +$34.9M +900,000 New
APM
25
Avidity Partners Management
Texas
$40.4M +$11.6M +300,500 +55%
1
2 3 4 5

RARE Hedge Fund Activity: Q4 2023 in Review

236 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2023, worth a combined $3.87B — up 54% from $2.52B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new RARE positions and 23 closed out — a net gain of 21 holders — while 94 added to existing stakes and 75 trimmed.

The largest buyer was Sands Capital Management, adding an estimated $59.7M. The largest seller was Avoro Capital Advisors, cutting an estimated $44.6M.

  • 236 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2023, up from 219 in Q3 2023.
  • Funds reported $3.87B of Ultragenyx Pharmaceutical stock for Q4 2023, up 54% quarter-over-quarter.
  • 44 funds opened new Ultragenyx Pharmaceutical positions in Q4 2023 and 23 closed out, a net change of +21 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q4 2023 was Sands Capital Management, an estimated $59.7M added.
  • The largest Ultragenyx Pharmaceutical seller in Q4 2023 was Avoro Capital Advisors, an estimated $44.6M sold.

Based on aggregated 13F filings for Q4 2023.